ATE549017T1 - Verwendung von tranilast und seinen derivaten zur behandlung von neurologischen zuständen - Google Patents

Verwendung von tranilast und seinen derivaten zur behandlung von neurologischen zuständen

Info

Publication number
ATE549017T1
ATE549017T1 AT08787273T AT08787273T ATE549017T1 AT E549017 T1 ATE549017 T1 AT E549017T1 AT 08787273 T AT08787273 T AT 08787273T AT 08787273 T AT08787273 T AT 08787273T AT E549017 T1 ATE549017 T1 AT E549017T1
Authority
AT
Austria
Prior art keywords
tranilast
derivatives
neurological conditions
treatment
neuronal
Prior art date
Application number
AT08787273T
Other languages
English (en)
Inventor
Armin Schneider
Anja Moraru
Carola Krueger
Rico Laage
Claudia Pitzer
Original Assignee
Sygnis Bioscience Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sygnis Bioscience Gmbh & Co Kg filed Critical Sygnis Bioscience Gmbh & Co Kg
Application granted granted Critical
Publication of ATE549017T1 publication Critical patent/ATE549017T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08787273T 2007-08-17 2008-08-15 Verwendung von tranilast und seinen derivaten zur behandlung von neurologischen zuständen ATE549017T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07016189A EP2030617A1 (de) 2007-08-17 2007-08-17 Verwendungen von Tranilast und Derivaten daraus zur Behandlung neurologischer Leiden
PCT/EP2008/060745 WO2009024543A1 (en) 2007-08-17 2008-08-15 Use of tranilast and derivatives thereof for the therapy of neurological conditions

Publications (1)

Publication Number Publication Date
ATE549017T1 true ATE549017T1 (de) 2012-03-15

Family

ID=38645596

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08787273T ATE549017T1 (de) 2007-08-17 2008-08-15 Verwendung von tranilast und seinen derivaten zur behandlung von neurologischen zuständen

Country Status (6)

Country Link
US (1) US20110112187A1 (de)
EP (2) EP2030617A1 (de)
AT (1) ATE549017T1 (de)
AU (1) AU2008290583A1 (de)
CA (1) CA2696582A1 (de)
WO (1) WO2009024543A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX352516B (es) * 2006-07-05 2017-04-06 Fibrotech Therapeutics Pty Ltd Compuestos terapeuticos.
CA2709937C (en) * 2007-12-21 2016-03-22 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
EP2947073B1 (de) 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Analoga von antifibriotischen mitteln mit kondensierten ringen
IN2014DN09031A (de) 2012-03-30 2015-05-22 Nuformix Ltd
EP3135280B1 (de) * 2014-04-24 2023-09-20 Omoidesouzou Co. Ltd. Tranilast zur behandlung von kutaner amyloidose
KR101733085B1 (ko) 2016-04-20 2017-05-08 전남대학교산학협력단 귀리 추출물 아베난쓰라마이드 c 또는 이의 유도체를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약제학적 조성물 및 건강기능식품
SG11201907139UA (en) 2017-02-03 2019-09-27 Certa Therapeutics Pty Ltd Anti-fibrotic compounds
EP3848052A4 (de) 2018-09-07 2022-06-08 Farnex Incorporated Äusserliche zubereitung mit nicht-lamellarem flüssigkristall formendem lipid
WO2024051844A1 (zh) * 2022-09-09 2024-03-14 北京达尔文细胞生物科技有限公司 用于防治急性期面神经麻痹的药物组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE222759T1 (de) * 1996-02-07 2002-09-15 Lead Chem Co Ltd Tranilast enthaltendes externum und verfahren zu dessen herstellung
WO2004071531A1 (en) * 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
WO2006076580A2 (en) * 2005-01-14 2006-07-20 The Board Of Trustees Of The Leland Stanford Junior University A method of modulating t cell functioning
EP1824469A4 (de) * 2004-11-17 2008-07-30 Nuon Therapeutics Pty Ltd Verfahren zur modulierung der b-zell-funktion
WO2006122353A1 (en) * 2005-05-16 2006-11-23 Angiogen Pharmaceuticals Pty. Ltd. Methods and compositions for the treatment of pain

Also Published As

Publication number Publication date
US20110112187A1 (en) 2011-05-12
EP2185150B1 (de) 2012-03-14
AU2008290583A1 (en) 2009-02-26
CA2696582A1 (en) 2009-02-26
WO2009024543A1 (en) 2009-02-26
EP2185150A1 (de) 2010-05-19
EP2030617A1 (de) 2009-03-04

Similar Documents

Publication Publication Date Title
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
EA201100441A1 (ru) Соединения для коррекции уровня мочевой кислоты и способы их применения
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
WO2009011871A3 (en) Thiadiazole modulators of pkb
MY148985A (en) 2-aminopyridine analogs as glucokinase activators
WO2008046003A3 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
IL211592A0 (en) Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
DE60330181D1 (de) Actriib-fusionspolypeptide und verwendungen dafür
TW200738657A (en) Thiazole compounds and methods of use
CR11383A (es) Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus
WO2009011880A3 (en) Heterocyclic modulators of pkb
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
BRPI0810942A2 (pt) método para tratar, previnir, retardar o início ou o desenvolvimento de uma condição, método para promover a diferenciação ou proliferação de uma célula, método para estimular o crescimento de neuritos ou para intensificar a neurogênese num indivíduo, método para auxiliar no tratamento de um indivíduo, método para diferenciar células-tronco multipotenciais, composição farmacêutica, e kit.
DE602007011908D1 (de) Verwendung von gpr119-rezeptoragonisten zur vermehrung der knochenmasse und zur behandlung von osteoporose sowie kombinationstherapie dafür
BRPI0815715A8 (pt) Compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases.
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
PA8780101A1 (es) Imidazopiridazina y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
WO2008156685A3 (en) Tendon stem cells
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
ATE501718T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
ATE460936T1 (de) Pyrazoloä1,5-aüpyrimidine derivate zur verwendung in der behandlung von morbus alzheimer und verwandten leiden
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid